This content is from: Corporate

Why Pfizer-Allergan inversion criticism is misplaced

The record-breaking merger has attracted fierce criticism, but the focus should be on US authorities’ deceptive use of guidance

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial